We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
This marks one of the most closely watched oncology readouts at this year’s medical congress
A one-shot gene-editing cholesterol therapy could soon be a reality
The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
Access to genomic testing, not therapy cost, is the biggest challenge
Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
Subscribe To Our Newsletter & Stay Updated
